NLRP3 and serum lipopolysaccharide activity: Since the NLRP3 inflammasome also mediates LPS-induced release of hIL-1β, we used the pharmacological NLRP3 inhibitor MCC950 (22) to test whether the endotoxemia model in huNSG-QUAD mice can be used to assess the efficacy and specificity of in vivo human NLRP3 inflammasome targeting.